이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Zhejiang Orient Gene BiotechLtd 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Xiaoliang Fang

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	7.3yrs
CEO 소유권	17.4%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	7.3yrs

최근 관리 업데이트

Recent updates

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) A Risky Investment?

Apr 30

CEO

Xiaoliang Fang (67 yo)

7.3yrs

테뉴어

CN¥1,152,900

보상

Mr. Xiaoliang Fang is GM & Director of Zhejiang Orient Gene Biotech Co., Ltd. from April 18, 2017.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Xiaoliang Fang	GM & Director	7.3yrs	CN¥1.15m	17.38% CN¥ 951.2m
Xiaoping Han	Independent Director	7.3yrs	CN¥100.00k	데이터 없음
Jianqiu Fang	Chairman	7.3yrs	CN¥1.25m	16.41% CN¥ 898.0m
Wei Lin	Independent Director	7.3yrs	CN¥100.00k	데이터 없음
Haiying Feng	Chairman of the Board of Supervisors	7.3yrs	데이터 없음	0.075% CN¥ 4.1m

7.3yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: 688298 의 이사회는 경험(평균 재직 기간 7.2 년)으로 간주됩니다.

Zhejiang Orient Gene BiotechLtd 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Zhejiang Orient Gene Biotech Co.,Ltd, Annual General Meeting, May 22, 2024

Recent updates

Zhejiang Orient Gene Biotech Co.,Ltd to Report First Half, 2024 Results on Aug 30, 2024

New major risk - Revenue and earnings growth

Zhejiang Orient Gene Biotech Co.,Ltd, Annual General Meeting, May 22, 2024

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) A Risky Investment?

Full year 2023 earnings released: CN¥1.97 loss per share (vs CN¥10.26 profit in FY 2022)

Now 21% undervalued after recent price drop

Zhejiang Orient Gene Biotech Co.,Ltd to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: CN¥1.85 loss per share (vs CN¥10.26 profit in FY 2022)

Zhejiang Orient Gene Biotech Co.,Ltd (SHSE:688298) announces an Equity Buyback for CNY 100 million worth of its shares.

Now 21% undervalued after recent price drop

Third quarter 2023 earnings released: CN¥0.55 loss per share (vs CN¥1.54 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.41 (vs CN¥3.35 in 2Q 2022)

Zhejiang Orient Gene Biotech Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Upcoming dividend of CN¥2.00 per share at 4.0% yield

First quarter 2023 earnings released: CN¥0.30 loss per share (vs CN¥12.30 profit in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥17.74 (vs CN¥29.29 in FY 2021)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥1.84 (vs CN¥3.12 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥4.02 (vs CN¥13.14 in 2Q 2021)

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Now 33% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Now 23% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥4.37 (vs CN¥1.17 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥18.40 (vs CN¥3.96 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥9.89 (vs CN¥0.37 in 1Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥14.07 (vs CN¥0.91 in FY 2019)

New 90-day low: CN¥135

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

New 90-day high: CN¥203

Investor sentiment improved over the past week

New 90-day high: CN¥177

Market bids up stock over the past week

Softlab9 Technologies Inc. Purchases Rapid Antigen COVID Testing Kits from Zhejiang Orient Gene Biotech Co. Ltd

New 90-day low - CN¥123

New 90-day high - CN¥260

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령